funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
HQ address
Ole Maaløes Vej 3, Copenhagen, DK-2200, DNK
Acesion Pharma is a Danish biotech company founded in 2011 by Morten Grunnet and Ulrik Sørensen together with the Danish venture funds Novo Seeds and SEED Capital.

Acesion Pharma is aiming for developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF is associated with impaired quality of life, increased rate of hospitalisation, and increased risk of stroke and death. It is recognised that existing drug therapies only have a limited effect and are often followed by risks of serious adverse events. Therefore, there is a high unmet need for better drugs for the medical treatment of AF.
The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats